AEST.MED.INT.HLD.SP.ADR/3 Cash Flow-to-Debt Ratio
AEST.MED.INT.HLD.SP.ADR/3 cash flow-to-debt ratio. AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has a Cash Flow-to-Debt Ratio of -0.02x as of December 2025, meaning its operating cash flow of €-12.23 Million could theoretically repay 0% of its total liabilities (€554.12 Million) in one year. See 3FMA free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of AEST.MED.INT.HLD.SP.ADR/3 (2021–2025)
Cash flow-to-debt ratio of AEST.MED.INT.HLD.SP.ADR/3 from 2021 to 2025. Historical debt coverage capacity for AEST.MED.INT.HLD.SP.ADR/3 across 5 annual periods. Check total reinvestment intensity of AEST.MED.INT.HLD.SP.ADR/3 to assess the company's total reinvestment commitment from operating cash flow.
AEST.MED.INT.HLD.SP.ADR/3 Cash Flow-to-Debt Ratio by Year (2021–2025)
AEST.MED.INT.HLD.SP.ADR/3 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for AEST.MED.INT.HLD.SP.ADR/3. For the full cash flow conversion analysis, see 3FMA cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | €-12.23 Million | €554.12 Million | ▼ -113.2% |
| 2024 | 0.17x | €79.67 Million | €476.88 Million | ▲ +18.5% |
| 2023 | 0.14x | €74.29 Million | €527.03 Million | ▲ +226.1% |
| 2022 | -0.11x | €-75.13 Million | €672.25 Million | ▼ -267.0% |
| 2021 | 0.07x | €51.09 Million | €763.36 Million | — |